<DOC>
	<DOCNO>NCT01606254</DOCNO>
	<brief_summary>The purpose study ass pharmacokinetics ( study way drug enters leave blood tissue time ) safety paliperidone palmitate participant schizophrenia ( psychiatric disorder symptom emotional instability , detachment reality , often delusion hallucination , withdrawal self ) .</brief_summary>
	<brief_title>A Pharmacokinetic Safety Study Paliperidone Palmitate ( JNS010 ) Participants With Schizophrenia</brief_title>
	<detailed_description>This multicenter ( one hospital medical school team work medical research study ) , open-label ( people know identity intervention ) , randomize ( study drug assign chance ) , parallel-group ( Each group participant treat time ) , comparison study ass pharmacokinetics safety paliperidone palmitate ( study medication ) participant schizophrenia . The study comprise 64-day Treatment period 155-day Follow-up period . The participant randomly assign one four study group . The study medication administer Days 1 , 8 , 36 64 . Pharmacokinetics study medication assess primary outcome . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Inclusion Criteria Participants diagnose schizophrenia accordance diagnostic criterion Diagnostic Statistical Manual Mental Disorders 4th edition ( DSMIV ) Participants may inpatients outpatient Participants take oral antipsychotic medication least 28 day date inform consent Participants Positive Negative Syndrome Scale ( PANSS ) score less equal 4 ( moderate ) screening Participants take risperidone start investigational treatment record confirm Exclusion Criteria Participants diagnose mental disease schizophrenia accordance diagnostic criterion Diagnostic Statistical Manual Mental Disorders 4th edition ( DSMIV ) Participants diagnose substancerelated disorder ( except nicotine caffeine dependence ) Participants complicate parkinson 's disease ( progressive disorder central nervous system , see usually old person , muscle weakness , tremble sweat ) Participants complication history convulsive disease epilepsy ( seizure disorder ) Participants complication history cerebrovascular accident ( stroke ) , neuroleptic malignant syndrome ( high fever , rigid muscle , shake , confusion , sweat usual , increased heart rate blood pressure , muscle pain weakness ) physical exhaustion associate state dehydration ( lose water mineral body ) malnutrition</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Paliperidone Palmitate</keyword>
	<keyword>JNS010</keyword>
</DOC>